Drug companies are partnering with universities to develop drugs, and are even recruiting academic scientists. Critics are concerned about a possible conflict if for-profit private firms get too close to tax-exempt academic medical centers, but life-sciences attorney Van Ellis says Big Pharma needs to be innovative to fill its drug pipeline and academia is concerned about funding its research.

Related Summaries